With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

Sensorion has two therapeutic solutions being evaluated in clinical trials (SENS-111 to treat acute unilateral vestibulopathy and SENS-401 to treat sudden sensorineural hearing loss).

SENS-401 has been selected as the clinical drug candidate to prevent cisplatin-inducted hearing loss.



20171123 pipeline EN

Latest news

  • 18 Oct 2017

    2017 First-half results Read

  • 12 Sep 2017

    Sensorion’s Oral SENS-401 Prevented Cisplatin-Induced Hearing Loss By More than 50 Percent in Preclinical Study Read

Patient center

Corporate presentation